ArticleScience translational medicine2020
Spontaneous reversal of stenosis in tissue-engineered vascular grafts.
Article in Science translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04467671 (Prospective, Open-labeled, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of the Second-generation Tissue Engineered Vascular Graft as Vascular Conduits for Extracardiac Total Cavopulmonary Connection.), which is not on this map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective, Open-labeled, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of the Second-generation Tissue Engineered Vascular Graft as Vascular Conduits for Extracardiac Total Cavopulmonary Connection.
Who cites it
69 citing papers in PubMed.
- Acoustic Tweezers-Assisted Biomaterial Molding in Petri Dishes (TAMP) for Engineering Glioma Tissues With Controlled Cellular and Extracellular Matrix Architectures.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Small Diameter Vascular Grafts Made in Minutes.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Growth of Tissue-Engineered Vascular Grafts and Heart Valves As Pediatric Conduits.Annals of thoracic surgery short reports · 2026Article
- A multiscale computational model of ascending thoracic aortic aneurysm development in Marfan syndrome for in silico trials.Biomechanics and modeling in mechanobiology · 2026Article
- Article
- Hemodynamics-driven magnetoelastic vascular grafts for stenosis diagnosis.Nature biotechnology · 2026Article
- Spectrum of Congenital Heart Diseases in Iraqi Patients.The Eurasian journal of medicine · 2026Article
- Predicted Effects of Patient Variability and Notch Signaling on In Situ Vascular Tissue Engineering.Annals of biomedical engineering · 2026Article
- Optimized biomechanical design of a tissue engineered pulsatile Fontan conduit.NPJ Regenerative medicine · 2026Article
- Don't judge an implant by its cover: how the foreign body response and fibrotic capsule might be harnessed for good.npj biomedical innovations · 2026Review
- In vitro and in vivo hemocompatibility study of fish swim bladder-derived biomaterials for the application of chronic venous disease.Journal of materials science. Materials in medicine · 2025Article
- A comprehensive framework for computational modeling of growth and remodeling in tissue-engineered soft collagenous materials.Biomechanics and modeling in mechanobiology · 2025Article
- Modulating the platelet-mediated innate foreign body response to affect in situ vascular tissue engineering outcomes.NPJ Regenerative medicine · 2025Article
- Oversized Conduits Predict Stenosis in Tissue Engineered Vascular Grafts.JACC. Basic to translational science · 2025Article
- Physiological Response of Tissue-Engineered Vascular Grafts to Vasoactive Agents in an Ovine Model.Tissue engineering. Part C, Methods · 2025Article
- Tissue Engineered Vascular Grafts: A Quarter Century Journey of Courage, Challenge, and Persistence.JACC. Basic to translational science · 2025Article
- Constrained optimization of scaffold behavior for improving tissue engineered vascular grafts.Journal of biomechanics · 2025Article
- Vascular endothelial cells derived from transgene-free pig induced pluripotent stem cells for vascular tissue engineering.Acta biomaterialia · 2025Article
- Fully biologic endothelialized-tissue-engineered vascular conduits provide antithrombotic function and graft patency.Cell stem cell · 2025Article
- Evaluation of in situ tissue-engineered arteriovenous grafts suitable for cannulation in a large animal model.Communications materials · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
Abstract
We developed a tissue-engineered vascular graft (TEVG) for use in children and present results of a U.S. Food and Drug Administration (FDA)-approved clinical trial evaluating this graft in patients with single-ventricle cardiac anomalies. The TEVG was used as a Fontan conduit to connect the inferior vena cava and pulmonary artery, but a high incidence of graft narrowing manifested within the first 6 months, which was treated successfully with angioplasty. To elucidate mechanisms underlying this early stenosis, we used a data-informed, computational model to perform in silico parametric studies of TEVG development. The simulations predicted early stenosis as observed in our clinical trial but suggested further that such narrowing could reverse spontaneously through an inflammation-driven, mechano-mediated mechanism. We tested this unexpected, model-generated hypothesis by implanting TEVGs in an ovine inferior vena cava interposition graft model, which confirmed the prediction that TEVG stenosis resolved spontaneously and was typically well tolerated. These findings have important implications for our translational research because they suggest that angioplasty may be safely avoided in patients with asymptomatic early stenosis, although there will remain a need for appropriate medical monitoring. The simulations further predicted that the degree of reversible narrowing can be mitigated by altering the scaffold design to attenuate early inflammation and increase mechano-sensing by the synthetic cells, thus suggesting a new paradigm for optimizing next-generation TEVGs. We submit that there is considerable translational advantage to combined computational-experimental studies when designing cutting-edge technologies and their clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.